Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT06481163

Telacebec (T) Treatment in Adults With Buruli Ulcer (BU).

Led by Barwon Health · Updated on 2025-12-10

140

Participants Needed

2

Research Sites

125 weeks

Total Duration

On this page

Sponsors

B

Barwon Health

Lead Sponsor

G

Global Alliance for TB Drug Development

Collaborating Sponsor

AI-Summary

What this Trial Is About

The goal of this interventional clinical trial is to determine if treatment with 2-4 weeks of telacebac (T) will completely heal lesions in participants with Buruli ulcer (BU) by 52 weeks after treatment initiation, without relapse and/or surgery. Males and females age 18 and older will be included. • Participants will attend visits every 2 weeks during treatment and thereafter every 2 weeks until week 24 Thereafter they will be followed by visits at weeks 30, 40, and 52. From week 10 to week 52, if the lesion has healed, follow-up visits may be remote.

CONDITIONS

Official Title

Telacebec (T) Treatment in Adults With Buruli Ulcer (BU).

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Clinical diagnosis of Buruli ulcer
  • Positive PCR or culture confirming Mycobacterium ulcerans infection
  • Age 18 years or older
Not Eligible

You will not qualify if you...

  • Any non-Buruli ulcer medical condition that could affect safety or study assessments as judged by the Investigator
  • History or current ascites, jaundice, myasthenia gravis, or significant kidney dysfunction (eGFR < 30 mls/min)
  • History of Buruli ulcer within the past 12 months (except current infection)
  • Planned or expected need for curative excision surgery for Buruli ulcer during the study period (simple removal of necrotic tissue and skin grafting allowed)

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

Barwon Health

Geelong, Victoria, Australia, 3220

Actively Recruiting

2

Royal Melbourne Hospital

Melbourne, Australia

Actively Recruiting

Loading map...

Research Team

B

Bree Sarah

CONTACT

K

Kate Ellis

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here